A perfect response and a long progression-free survival (PFS) were reached with tumor mass disappearing...
Raleigh, NC (PRWEB) April 12, 2016
A new report from a Chinese medical center suggests that advanced mesothelioma patients may have a more promising option than the standard therapy for extending their survival. Surviving Mesothelioma has just published details of the new report. Click here to read the full article.
Doctors with Shandong Cancer Hospital and Institute treated an advanced pleural mesothelioma patient with a three-drug chemotherapy combination followed by six courses of “maintenance therapy” with pemetrexed (brand name Alimta).
“Residual tumor disappeared after six courses of pemetrexed maintenance therapy (PMT),” reports Xue-Qing Jing, lead author on the report. ”A perfect response and a long progression-free survival (PFS) were reached with tumor mass disappearing and 14 months duration of PFS.”
The report, published in the journal Medicine, suggests that adding PMT to chemotherapy for pleural mesothelioma that includes bevacizumab (brand name Avastin) is potentially both “promising and useful”.
“We are excited to share this news with mesothelioma patients and families, especially because the current standard of case for pleural mesothelioma is limited at best,” says Surviving Mesothelioma’s Managing Editor, Alex Strauss.
To find out more about PMT and the Chinese case study, see New Drug Regimen Produces “Perfect Response” in Advanced Mesothelioma Case, available now on the Surviving Mesothelioma website.
For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.